Trials / Completed
CompletedNCT04632927
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
A 28-week, Randomized, Double-blind, Active Controlled, Multicenter Study to Evaluate the Efficacy of Subcutaneously Administered Secukinumab Compared to Ustekinumab in Adult Patients With Psoriatic Arthritis and Failure of TNFα- Inhibitor Treatment (AgAIN)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Secukinumab | Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio |
| BIOLOGICAL | Ustekinumab | Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio |
Timeline
- Start date
- 2020-12-21
- Primary completion
- 2024-10-22
- Completion
- 2024-10-22
- First posted
- 2020-11-17
- Last updated
- 2025-10-16
- Results posted
- 2025-10-16
Locations
28 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT04632927. Inclusion in this directory is not an endorsement.